Not sure but she's been with the company 5 years.The new Chief...

Not sure but she's been with the company 5 years.
The new Chief Medical Officer, Dr.Donna Skerrett has extensive experience with US FDA IND filings.
They've done well so far, are you concerned glacier?

.....

Chief Executive Officer, Mr Paul Rennie, has been involved in drug development and a number of pre-clinical and clinical trial programs (was the inaugural COO of Mesoblast and most recently as Executive VP, New Product Development at Mesoblast Ltd). Mr. Rennie has extensive experience in commercialising Intellectual Property.

Chief Medical Officer, Dr.Donna Skerrett, joined the Paradigm team in September 2019. With more than 30 years’ experience in transfusion medicine, cellular therapy, and transplantation, she brings a wealth of experience in medical, clinical, and regulatory affairs. Donna served previously as Chief Medical Officer at Mesoblast. She was Director of Transfusion Medicine and Cellular Therapy at Weill Cornell Medical Center in New York (2004 – 2011), and prior to that was Associate Director of Transfusion Medicine and Director of Stem Cell Facilities at Columbia University’s New York-Presbyterian Hospital. She previously chaired the New York State Council on Blood and Transfusion Services and currently serves on the Board of Directors of the Fox Chase Cancer Center in Philadelphia, Pa.

Global Head of Clinical Development, Sharon Charles, has over 30 years’ experience in the healthcare sector across geographies, with 24 years in clinical and commercial development. She has a strong track record in developing world-class products and services and growing regional business. Sharon has worked at world leading biotech companies, including Amgen and CSL, and brings a depth of biotech development understanding and skill.

Chief Scientific Officer, Dr Ravi Krishnan, is a basic scientist with a long-standing interest and experience in experimental pathology, transplantation immunology, gene and stem cell therapy. He has also had significant experience in investigating novel compounds with immune modulatory effects, anti-inflammatory and anti-angiogenic properties.

Clinical Operations Manager, Melanie Duiker, joined the Paradigm team in 2017. With over 25 years of experience in clinical research, she is responsible for the coordination and oversight of our clinical research activities within Australia and abroad. Her industry experience includes managing clinical operations at local, as well as international level, with 8 years managing clinical operations with Europe. Melanie brings broad experience in clinical study development and operations, including: Feasibility, Forecasting and budget management, Quality Management, Audit Management and Vendor Management.

Non-Executive Chairman, Mr Graeme Kaufman, has broad experience in the development and commercialisation of pharmaceutical drugs (prior executive roles including CFO at CSL Limited, executive VP of Mesoblast Ltd).

Project Manager, Jill Forrest, has over 30 years’ experience working in healthcare, with 20 years in the clinical research industry. Her experience in clinical research ranges from working as a study coordinator, clinical research associate and clinical research consultant across phase I-III trials. Jill has worked at world leading pharmaceutical companies, including Pfizer and AstraZeneca, and brings with her a broad understanding of project and site management.